GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer

Gao,De‑Yong; Ling,Yun; Lou,Xiao‑Li; Wang,Ying‑Ying; Liu,Liang‑Ming

doi:10.3892/ol.2017.7695

GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer

Authors:
- De‑Yong Gao
- Yun Ling
- Xiao‑Li Lou
- Ying‑Ying Wang
- Liang‑Ming Liu
View Affiliations

Affiliations: Department of Infectious Diseases, Songjiang Hospital Affiliated to Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 201600, P.R. China, Department of Infectious Diseases, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 200083, P.R. China
Published online on: December 27, 2017 https://doi.org/10.3892/ol.2017.7695
Pages: 3133-3140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gametocyte-specific factor 1 (GTSF1) gene participates in DNA methylation and retrotransposon activation in germ cells, particularly during cell proliferation. The present study aimed to assess the level of GTSF1 gene expression in liver cancer tumor tissues, and its role in human hepatoma cell lines in vitro and in a nude mouse model in vivo. GTSF1 gene expression was detected in liver cancer tumor tissues, compared with in healthy controls, via reverse transcription quantitative polymerase chain reaction. An adeno‑associated virus vector was used to study tumor stem cell proliferation in vivo. A plasmid expressing GTSF1 was constructed and transfected into various human hepatoma cell lines, in order to analyze the cellular proliferation and apoptosis of liver cancer cells using small interfering (si)RNAs in vitro. In the present study, GTSF1 gene expression was detected in 18/24 (75.0%) liver cancer tumor tissues from patients with hepatocellular carcinoma (HCC), and elevated GTSF1 expression was identified in the tissue of one of 32 healthy control samples (3.13%; P<0.05). Notably, the GTSF1 gene was expressed at a higher frequency in AFP‑positive HCC samples (14/16, 87.50%) compared with in AFP‑negative HCC samples (4/8, 50.0%; P=0.129). In addition, there was no statistical significance between GTSF1 expression in non‑HBV‑infected (71.42%) and HBV‑infected HCC specimens (76.47%), as determined by a χ2 test (P=0.921). It was demonstrated that GTSF1 significantly increased the tumorigenicity of Ad‑shNC‑transfected (GTSF1‑positive) HepG2 cells in the nude mouse xenograft model, whereas the sizes and weights of the tumors in the GTSF1‑negative group were dercreased in comparison with the GTSF1‑positive group (P<0.05). Reduced levels of GTSF1 mRNA, along with fewer and smaller colonies, were identified in two groups of human liver cancer cells treated with with GTSF1‑targeting siRNA, when compared with cells without GTSF1 mRNA interference (P<0.05). In summary, the present study elucidated the GTSF1 mRNA expression pattern in liver cancer, and investigated the potential role of GTSF1 in tumorigenesis. The data suggest an important role for the GTSF1 gene in the molecular etiology of hepatocarcinogenesis, and indicate a potential application of GTSF1 mRNA expression in liver cancer diagnosis and therapy.

View Figures

View References

1	Balogh J, Victor D III, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour HP Jr.: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma. 3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Caldwell S and Park SH: The epidemiology of hepatocellular cancer: From the perspectives of public health problem to tumor biology. J Gastroenterol. 44 Suppl 19:S96–S101. 2009. View Article : Google Scholar
4	Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, et al: Hepatocellular carcinoma (HCC): A global perspective. J Clin Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y and Nakatsura T: Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 21:10573–10583. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zucman-Rossi J, Villanueva A, Nault JC and Llovet JM: Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 149:1226–1239.e4. 2015. View Article : Google Scholar : PubMed/NCBI
7	Yoshimura T, Toyoda S, Kuramochi-Miyagawa S, Miyazaki T, Miyazaki S, Tashiro F, Yamato E, Nakano T and Miyazaki J: Gtsf1/Cue110, a gene encoding a protein with two copies of a CHHC Zn-finger motif, is involved in spermatogenesis and retrotransposon suppression in murine testes. Dev Biol. 335:216–227. 2009. View Article : Google Scholar : PubMed/NCBI
8	Krotz SP, Ballow DJ, Choi Y and Rajkovic A: Expression and localization of the novel and highly conserved gametocyte-specific factor 1 during oogenesis and spermatogenesis. Fertil Steril. 91(5 Suppl): S2020–S2024. 2009. View Article : Google Scholar
9	van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R, Willemze R and Tensen CP: A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol. 132:2050–2059. 2012. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Shimizu D, Inokawa Y, Sonohara F, Inaoka K and Nomoto S: Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review). Oncol Rep. 37:2527–2542. 2017. View Article : Google Scholar : PubMed/NCBI
12	Shao YY, Hsu CH and Cheng AL: Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: Where are we? Liver Cancer. 2:93–107. 2013. View Article : Google Scholar : PubMed/NCBI
13	Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI
14	Yoshimura T, Miyazaki T, Toyoda S, Miyazaki S, Tashiro F, Yamato E and Miyazaki J: Gene expression pattern of Cue110: A member of the uncharacterized UPF0224 gene family preferentially expressed in germ cells. Gene Expr Patterns. 8:27–35. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, et al: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 299:53–60. 2008. View Article : Google Scholar : PubMed/NCBI
16	Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, et al: Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 43:828–829. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS and Shen XZ: Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: A systematic review. J Cancer Res Clin Oncol. 137:1095–1104. 2011. View Article : Google Scholar : PubMed/NCBI
18	Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB and Davis GL: Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 26:1187–1194. 2007. View Article : Google Scholar : PubMed/NCBI
19	Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K and Krawczyk M: Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 38:2698–2707. 2014. View Article : Google Scholar : PubMed/NCBI
20	Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C and Lencioni R: Using modified RECIST and alpha-fetoprotein levels to assess treatment benefit in hepatocellular carcinoma. Liver Cancer. 3:439–450. 2014. View Article : Google Scholar : PubMed/NCBI
21	Furihata T, Sawada T, Kita J, Iso Y, Kato M, Rokkaku K, Shimoda M and Kubota K: Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology. 55:1705–1709. 2008.PubMed/NCBI
22	Zhao YJ, Ju Q and Li GC: Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 1:593–598. 2013. View Article : Google Scholar : PubMed/NCBI
23	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
24	Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D and Zhong XB: A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos. 38:988–994. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wiśniewski JR, Vildhede A, Norén A and Artursson P: In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. J Proteomics. 136:234–247. 2016. View Article : Google Scholar : PubMed/NCBI
26	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cevik D, Yildiz G and Ozturk M: Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 21:311–317. 2015. View Article : Google Scholar : PubMed/NCBI
28	Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi V, Wongkham S and Svasti J: Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol. 2010:4371432010. View Article : Google Scholar : PubMed/NCBI
29	Wadee AA, Paterson A, Coplan KA and Reddy SG: HLA expression in hepatocellular carcinoma cell lines. Clin Exp Immunol. 97:328–333. 1994. View Article : Google Scholar : PubMed/NCBI
30	Dapas B, Farra R, Grassi M, Giansante C, Fiotti N, Uxa L, Rainaldi G, Mercatanti A, Colombatti A, Spessotto P, et al: Role of E2F1-cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs. Mol Med. 15:297–306. 2009. View Article : Google Scholar : PubMed/NCBI
31	Farra R, Dapas B, Pozzato G, Giansante C, Heidenreich O, Uxa L, Zennaro C, Guarnieri G and Grassi G: Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie. 92:455–463. 2010. View Article : Google Scholar : PubMed/NCBI
32	Spänkuch B and Strebhardt K: Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Curr Pharm Des. 14:1098–1112. 2008. View Article : Google Scholar : PubMed/NCBI
33	Farra R, Grassi M, Grassi G and Dapas B: Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol. 21:8994–9001. 2015. View Article : Google Scholar : PubMed/NCBI